Cure Hepatitis C Act of 2026 (H.R. 9682)
Referred to CommitteeLatest Action
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
7/14/2026 • House
Summary
Cure Hepatitis C Act of 2026
This bill establishes programs and requirements to provide free medications to treat hepatitis C in certain high-risk or vulnerable populations. It also establishes grants and other resources to support testing and treatment for hepatitis C. The bill provides funding for FY2027 to implement these provisions.
The Department of Health and Human Services (HHS) must enter into a five-year purchasing contract with manufacturers of drugs that treat hepatitis C so that eligible individuals may receive the drugs without cost-sharing. Eligible individuals are those diagnosed with hepatitis C who are (1) enrolled in Medicaid or the Children’s Health Insurance Program (CHIP), (2) confined to federal, state, or local correctional facilities (or were released and began treatment there), (3) uninsured, or (4) receiving health care through the Indian Health Service.
State Medicaid and CHIP programs and state and local correctional facilities may opt into the program; participation is mandatory for federal correctional facilities and the Indian Health Service.
HHS must award grants to certain entities, including states, public health organizations, and correctional facilities, to support the coordination and provision of screening, treatment, and supportive services for the affected populations.
The bill also allows Medicare beneficiaries to receive hepatitis C drugs without cost-sharing from 2028-2032.
Introduced in House • 7/14/2026
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (7)
Party Breakdown
Sponsor
Cosponsors (6)
Bill Journey
Originated in the House
Introduced
July 14, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Related Bills (1)
Committees
Details
Sources and method
· Congress.gov, CRS, USAspending, FEC, LDA · Record updated Oct 6, 2026
- Congress.govLibrary of CongressStatus, actions, sponsors, cosponsors, committees and textRecord updated Oct 6, 2026 · Loaded Oct 28, 2026, 4:10 PM ET
- CRS bill summaryCongressional Research Service, via Congress.govOfficial summarySummary of the “Introduced in House” version, Jul 14, 2026 · Loaded Oct 28, 2026, 4:10 PM ET
- USAspending.govU.S. Department of the TreasuryRelated Federal Spending section
- FEC filingsFederal Election CommissionFunding & Lobbying section
- Lobbying disclosures (LDA)Secretary of the Senate and Clerk of the HouseFunding & Lobbying section
All sources: Public domain (17 U.S.C. § 105) · Method: Data sources → · Campaign finance →
AI-written text on this page is labeled where it appears. It is written from the sources above and is not a source itself. How we analyze data →
Dates shown where the source reports one. “Loaded” is when CIV.IQ last fetched the record.